Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Vascular endothelial growth factor receptors (VEGFRs) are crucial for tumor angiogenesis.
• Current VEGFR inhibitors have limitations in clinical efficacy and toxicity.
• There is a need for improved therapeutic strategies targeting VEGFRs.

Purpose of the Study:

• To provide an overview of VEGFR dual-target inhibitors.
• To discuss rational target combinations for dual-inhibition strategies.
• To explore drug discovery, structure-activity relationships, and future directions for VEGFR dual-target inhibitors.

Main Methods:

• Literature review and analysis of existing research on VEGFR inhibitors.
• Examination of synergistic effects between VEGFR and other therapeutic targets.
• Discussion of drug design principles and structure-activity relationships for dual-target inhibitors.

Main Results:

• VEGFR dual-target inhibitors present a promising approach with potential for improved pharmacodynamics.
• These inhibitors may offer reduced toxicity and overcome resistance mechanisms.
• Synergistic effects with other therapies enhance anti-tumor activity.

Conclusions:

• VEGFR dual-target inhibitors represent an attractive strategy for cancer therapy.
• Further research into rational target combinations and drug discovery is warranted.
• Optimizing dual-target inhibitors can lead to improved clinical outcomes and reduced side effects.